KemPharm Inc

NASDAQ:KMPH  
4.97
-0.14 (-2.84%)
Products, Regulatory

Kempharm Announces Full Data Set From Higher-Dose Serdexmethylphenidate Phase 1 Clinical Trial

Published: 03/21/2022 12:58 GMT
KemPharm Inc (KMPH) - Kempharm Announces Full Data Set From Higher-dose Serdexmethylphenidate (sdx) Phase 1 Clinical Trial.
Kempharm Inc - Anticipate Kp1077 Ind Filing As Early As Q2 2022.
Kempharm - Anticipate Phase 2 Trial Initiation in Ih Patients, Announce Results of Study to Examine Safety Related to Cardiovascular Effects 2h 2022.
Kempharm Inc - Data Generated in Phase 1 Trial of Higher-dose Sdx Suggest That Kp1077 is Well-tolerated.